INFED

Compare INFED  to:
Compare
Compare

Generic Name for INFED

Iron (as dextran complex) 50mg/mL; soln for IV or IM inj.

Legal Classification:

Rx

Pharmacological Class for INFED

Hematinic.

Manufacturer of INFED

Watson Pharmaceuticals, Inc.

Indications for INFED

Iron deficiency where oral therapy is unsatisfactory or impossible.

Adults and Children:

Give by IV or by deep IM (into upper outer quadrant of buttock only) inj. Administer 0.5mL test dose first; if no signs/symptoms of anaphylactic-type reactions, may give full therapeutic dose. Iron deficiency anemia: determine total dose based on hemoglobin and body weight (see literature). Iron replacement for blood loss: Replacement iron (in mg) = blood loss (in mL) X hematocrit. Max daily doses: <5kg: 0.5mL (25mg), <10kg: 1mL (50mg), ≥10kg: 2mL (100mg).

Contraindications for INFED

Anemias not associated with iron deficiency.

Precautions for INFED

Monitor for signs/symptoms of anaphylactic-type reactions, esp. in patients with history of drug allergies, asthma; have epinephrine available. Avoid large IV doses: higher incidence of adverse events. Severe hepatic impairment. Avoid during acute phase of infectious kidney disease. Dialysis. Cardiovascular disease. May reactivate quiescent rheumatoid arthritis. Neonates (avoid during first 4 months). Pregnancy (Cat. C). Nursing mothers.

Interactions for INFED

Concomitant ACE inhibitors may increase the risk for anaphylactic-type reactions. May falsely elevate serum bilirubin or decrease serum calcium levels.

Adverse Reactions for INFED

See literature. Anaphylactic reactions (may be fatal; even if test dose was tolerated), cardiovascular events, pruritus, GI upset, arthralgia, arthritis, inj site reactions, others; possible IM inj site tumors, sepsis in neonates.

How is INFED supplied?

Vials (2mL)—10

Related Disease:

Anemia

Related Resources

Vpriv available for Type 1 Gaucher disease

March 01, 2010

Shire announced that Vpriv (velaglucerase alfa for injection) has been FDA approved and made available for the treatment of Type 1 Gaucher disease.

FDA cancer drug approval rate reviewed in JNCI

February 19, 2010

The FDA's Office of Oncology Drug Products approved 53 new indications for the use of oncology and hematology drugs and biologics from July 2005 to the end of 2007.

FDA announces safety plan for erythropoiesis-stimulating agents

February 16, 2010

The FDA has approved a risk management program to inform healthcare providers and patients about the risks of erythropoiesis-stimulating agents (ESAs).

Phase 3 study of velaglucerase alfa for the treatment of type 1 Gaucher disease

February 11, 2010

Shire presented positive results from its first Phase 3 study (TKT032) of velaglucerase alfa for the treatment of Type 1 Gaucher disease.

Feraheme safety update

February 08, 2010

AMAG Pharmaceuticals has provided a safety update on Feraheme (ferumoxytol injection) indicating that serious adverse events have been reported at a rate consistent with that contained in the Prescribing Information.